Publications by authors named "E Jost"
Article Synopsis
- The European LeukemiaNet (ELN) updated its risk classification for acute myeloid leukemia (AML) patients in 2022 (ELN22) and a study evaluated its effectiveness on 1,570 newly diagnosed patients.
- Compared to the previous 2017 classification (ELN17), the new ELN22 showed a similar distribution of risk categories but reclassified 22% of patients, mostly into intermediate or adverse groups, resulting in better prognostic accuracy, particularly for overall survival (OS).
- The study found significant differences in survival rates based on specific gene mutations within the adverse risk group, highlighting the need for tailored treatment approaches based on genetic factors.
Photoplethysmography Features Correlated with Blood Pressure Changes.
Diagnostics (Basel)
October 2024
Blood pressure measurement is a key indicator of vascular health and a routine part of medical examinations. Given the ability of photoplethysmography (PPG) signals to provide insights into the microvascular bed and their compatibility with wearable devices, significant research has focused on using PPG signals for blood pressure estimation. This study aimed to identify specific clinical PPG features that vary with different blood pressure levels.
View Article and Find Full Text PDFArticle Synopsis
- Rasmussen's encephalitis (RE) is a rare disorder causing severe seizures and brain atrophy in children, often requiring surgical intervention when treatments fail.
- A case study highlights a woman who had a left hemispherectomy at age seven and successfully went through two pregnancies, experiencing temporary worsening of her symptoms during each but returning to her baseline afterward.
- This situation underscores the lack of data on RE and pregnancy, emphasizing the need for careful monitoring and an interdisciplinary approach to ensure the health and safety of both mother and child during and after pregnancy.
In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse-risk genetics, without adding toxicity. We performed a post hoc analysis to determine the predictive impact of TP53 status. Despite a nominally higher ORR, the clinically meaningful survival benefit when adding ATRA to DEC was diminished, but not completely negated, in TP53-mutated patients.
View Article and Find Full Text PDF